Histologic and combined histologic-endoscopic outcomes with mirikizumab in Crohn's disease: VIVID-1 trial results. | ClinicLens
Evaluation of microscopic inflammation is an emerging therapeutic target of Crohn's disease. The completed VIVID-1 trial evaluated histologic and combined histologic-endoscopic outcomes for mirikizumab relative to placebo and ustekinumab in moderately-to-severely active Croh
Medical Literature · Updated
← Back to articlesIf the embedded page does not load in your browser, open it directly.